Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cells

HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia

Leukemia volume 21, pages 129–135 (2007)Cite this article

Abstract

We conducted a retrospective registry-based analysis to compare the outcome of 361 allogeneic human leukocyte antigen (HLA)-identical peripheral blood stem cell transplants (PBSCT) with reduced intensity conditioning (RIC) to that of 1369 autologous (auto) PBSCT in patients aged 50 years or older with de novo acute myeloid leukemia (AML), performed from 1997 until 2003 and reported to the European Group for Blood and Marrow Transplantation. Median age was 58 and 57 years in the RIC and auto groups, respectively. RIC patients had more advanced disease at the time of transplant. At a median follow-up of 24 months for RIC and 16 months for auto, multivariate analysis showed a lower risk for relapse (RR 0.77, P=0.013) without increased non-relapse mortality (NRM) in RIC patients (RR 1.26, P=0.28). Moreover, leukemia-free survival (RR 1.22, P=0.02) and overall survival (OS) (RR 1.32, P=0.005) were superior in the RIC group. In patients in 1st (CR), fewer relapses were counterbalanced by significantly increased NRM. Therefore, there was no survival advantage in this subgroup. In patients in 2nd or subsequent CR, LFS and OS were superior in the RIC group. RIC transplants show encouraging results in this older patient population with de novo AML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Stone RM, O'Donnell MR, Sekeres MA . Acute myeloid leukemia. ASH Education Program Book 2004, 98–117.

  2. Estey EH . How I treat older patients with AML. Blood 2000; 96: 1670–1673.

    CAS  PubMed  Google Scholar 

  3. Ferrara F . Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5: 443–450.

    Article  PubMed  Google Scholar 

  4. Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglund M, Karlsson K et al. Attitude towards remission induction for elderly patients with acute myeloid leukaemia influences survival. Leukaemia 2006; 20: 42–47.

    Article  CAS  Google Scholar 

  5. Gorin NC . Autologous stem cell transplantation in acute myeloid leukemia. Blood 1998; 92: 1073–1090.

    CAS  PubMed  Google Scholar 

  6. Breems DA, Löwenberg B . Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol 2005; 130: 825–833.

    Article  PubMed  Google Scholar 

  7. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–223.

    Article  CAS  PubMed  Google Scholar 

  8. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656.

    Article  CAS  PubMed  Google Scholar 

  9. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study. Leukemia 1996; 10: 1874–1882.

    CAS  PubMed  Google Scholar 

  10. Suciu S, Mandelli F, de Witte T, Zottoun R, Gallo E, Labar B et al. Allogeneic compared to autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003; 102: 1232–1240.

    Article  CAS  PubMed  Google Scholar 

  11. Ringden O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993; 270: 57–60.

    Article  CAS  PubMed  Google Scholar 

  12. Niederwieser D, Gentilini C, Hegenbart U, Lange T, Becker C, Wang SY et al. Allogeneic hematopoietic cell transplantation (HCT) following reduced intensity conditioning in patients with acute leukemias. Crit Rev Oncol Hematol 2005; 56: 275–281.

    Article  PubMed  Google Scholar 

  13. Slavin S, Nagler A, Naparstek Y, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  14. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    CAS  PubMed  Google Scholar 

  15. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D et al. The role of reduced intensity conditioning allogeneic stem cell transplanatation in patients with acute myeloid leukemia: a donor versus no donor comparison. Leukemia 2005; 19: 916–920.

    Article  CAS  PubMed  Google Scholar 

  16. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  PubMed  Google Scholar 

  17. Bertz H, Potthoff K, Finke J . Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1484–1840.

    Article  Google Scholar 

  18. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052–3059.

    Article  CAS  PubMed  Google Scholar 

  19. Sayer HG, Kröger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089–1095.

    Article  CAS  PubMed  Google Scholar 

  20. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shiruzu JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444–453.

    Article  CAS  PubMed  Google Scholar 

  21. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322–328.

    Article  CAS  PubMed  Google Scholar 

  22. Shimoni A, Kröger N, Yabelina T, Ayuk F, ardan I, Yeshurun M et al. Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukaemia 2005; 19: 7–12.

    Article  CAS  Google Scholar 

  23. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810–1814.

    Article  CAS  PubMed  Google Scholar 

  24. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–2312.

    Article  CAS  PubMed  Google Scholar 

  25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  26. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  27. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 665–706.

    Article  Google Scholar 

  28. Cox DR . Regression models and life tables. J Roy Stat Soc. 1972; 34: 187–202.

    Google Scholar 

  29. Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. Journal of American Statistical Association 1999; 94: 496–509.

    Article  Google Scholar 

  30. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    A-L Herr & A Rosselet

  2. Hôpital Saint-Antoine, APHP and Université Pierre et Marie Curie, Paris, France

    M Labopin & N C Gorin

  3. Institut Paoli Calmettes, Marseille, France

    D Blaise

  4. CHU Bordeaux Hôpital Haut-Lévèque, Pessac, France

    N Milpied

  5. Royal Marsden Hospital, London, UK

    M Potter

  6. Hôpital E Herriot, Lyon, France

    M Michallet

  7. Kliniken Essen Süd, Essen, Germany

    W Heit

  8. Cardarelli Hospital, Napoli, Italy

    F Ferrara

  9. Hospital Clinic, Barcelona, Spain

    J Esteve

  10. Tor Vergata University Hospital, Rome, Italy

    W Arcese

  11. Universitaetsklinikum Dresden, Dresden, Germany

    G Ehninger

  12. Rambam Medical Center, Haifa, Israel

    J M Rowe

  13. Heinrich Heine Universität, Klinik für Hämat, Düsseldorf, Germany

    G Kobbe

  14. Medizinische Klinik und Poliklinik, Ulm, Germany

    D Bunjes

  15. Hotel Dieu, Paris, France

    B Rio

  16. Sahlgrenska University Hospital, Goeteborg, Sweden

    M Brune

  17. Tel Aviv University, Chaim Sheba Medical Centre, Tel Hashomer, Israel

    A Nagler

  18. Hospital San Martino, Genova, Italy

    F Frassoni

  19. Hôpital Saint-Louis, APHP, Paris, France

    V Rocha

Authors
  1. A-L Herr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Heit
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Ferrara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Esteve
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W Arcese
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G Ehninger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J M Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G Kobbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Rosselet
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D Bunjes
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. B Rio
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M Brune
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. N C Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. F Frassoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. V Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Corresponding author

Correspondence to V Rocha.

Appendix

Appendix

List of participating centres with three or more RIC patients included:

Institut Paoli Calmettes, Marseille, France, D Blaise; CHU Bordeaux Hôpital Haut-Lévèque, Pessac, France, N Milpied; University of Leipzig, Leipzig, Germany, D Niederwieser; Hôpital A Michallon, Grenoble, France, JY Cahn; University Hospital Brno, Brno, Czech republic, J Mayer; Medizinische Klinik und Poliklinik, Ulm, Germany, D Bunjes; Sahlgrenska University Hospital, Goeteborg, Sweden, M Brune; University Hospital, Basel, Switzerland, A Gratwohl; University Hospital, Zürich, Switzerland, U Schanz; Medizinische Universitaet Wien, Vienna, Austria, H Greinix; Manchester Royal Infirmary, Manchester, UK, J Liu Yin; University Hospital Eppendorf, Hamburg, Germany, AR Zander; GKT School of Medicine King's Denmark Hill Campus, London, UK, GJ Mufti; Cliniques Universitaires St-Luc, Brussels, Belgium, A Ferrant; Hôpital Henri Mondor, Créteil, France, C Cordonnier; Hadassah University Hospital, Jerusalem, Israel, S Slavin; University Hospital Innsbruck, Innsbruck, Austria, G Gastl; Ospedale V Cervello, Palermo, Italy, R Scimè; University Hospital, Linköping, Sweden, N Theorin; Chaim Sheba Medical Centre, Tel-Hashomer, A Nagler; Plymouth Hospitals NHS Trust Derriford Hospital, Plymouth, UK, MD Hamon; University Medical centre, Utrecht, The Netherlands, LF Verdonck; Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands, JJ Cornelissen; Hotel Dieu, Nantes, France, JL Harousseau; Hospital Santa Creu I Sant Pau, Barcelona, Spain, J Sierra; Ospedale di Careegi, Firenze, Italy, A Bossi; Heinrich Heine Universität, Düsseldorf, Germany, G Kobbe; Hopital de Purpan, Toulouse, France, M Attal; Hôpital E Herriot, Lyon, France, M Michallet; Hopital Hautepierre, Strasbourg, France, B Lioure; Hospital Clínico, Salamanca, Spain, D Caballero; St. Bartholomew's and The Royal London Hospital West Smithfield, London, UK, J Gribben; Universitaetsklinikum Dresden, Dresden, Germany, G Ehninger; University of Freiburg, Freiburg, Germany, J Finke; HSS Antonio e Biagio, Alessandria, Italy, B Allione; Hotel Dieu, Paris, France, B Rio; Azienda Ospedaliera S Giovanni, Torino, Italy, M Falda; Hopital Jean Minjoz, Besançon, France, E Deconinck; St. James Hospital Trinity College, Dublin, Ireland, S McCann; Ospedale Niguarda Ca'Granda, Milano, Italy, S Siena; Policlinico San Matteo, Pavia, Italy, EP Alessandrino; Hannover Medical university, Hannover, Germany, B Hertenstein; Goethe-Universität Medizinische Klinik II, Frankfurt, Germany, D Hoelzer; University of Wales, Cardiff, UK, K Wilson; Policlinico Le Scotte, Siena, Italy, F Lauria; University Hospital Maastricht, Maastricht, The Netherlands, H Schouten; Institute of Hematology and Blood Transfusion, Prague, Czech Republic, A Vitek; Institut Gustave Roussy, Villejuif, France, JH Bourhis; University of Münster, Münster, Germany, J Kienast; Charles University Hospital, Pilsen, Czech Republic, V Koza; K Marcinkowski University of Medical Science, Pozna, Poland, M Komarnicki; Umea University Hospital, Umea, Sweden, A Wahlin; University of Saarland, Homburg, Germany, J Schubert; Charité Universitätsmedizin Berlin, Berlin, Germany, R Arnold.

List of participating centres with seven or more auto patients included:

Institut Paoli Calmettes, Marseille, France, D Blaise; Royal Marsden Hospital, London, UK, M Potter; Kliniken Essen Süd, Essen, Germany, W Heit; Cardarelli Hospital, Napoli, Italy, F Ferrara; Hôpital E Herriot, Lyon, France, M Michallet; University La Sapienza, Rome, Italy, R Foa; CHU Bordeaux Hôpital Haut-Lévèque, Pessac, France, N Milpied; Robert-Bosch-Krankenhaus, Stuttgart, Germany, S Martin; Hospital Clinic, Institute of Hematology and Oncology, Barcelona, Spain, E Carreras; Hotel Dieu, Paris, France, B Rio; Spedali Civili-Brescia, Brescia, Italy, G Rossi; Hannover Medical university, Hannover, Germany, B Hertenstein; Heinrich Heine Universität, Klinik für Hämat, Düsseldorf, Germany, G Kobbe; Hospital Universitario La Fe, Valencia, Spain, MA Sanz; Johannes-Gutenberg University, Mainz, Germany, K Kolbe; Universitaetsklinikum Dresden, Dresden, Germany, G Ehninger; Rambam Medical Center, Haifa, Israel, JM Rowe; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, A Rosselet; Hospital U Marqués de Valdecilla, Santander, Spain, A Iriondo Atienza; VU university Medical centre, Amsterdam, The Netherlands, GJ Ossenkoppele; Charles University Hospital, Hradec Králové, Czech Republic, L Jebavy; Hotel Dieu, Nantes, France, JL Harousseau; Medical University Graz, Graz, Austria, W Linkesch; Leiden University Hospital, Leiden, The Netherlands, R Willemze; Medizinische Klinik und Poliklinik, Ulm, Germany, D Bunjes; Karolinska University Hospital, Stockholm, Sweden, O Ringden; Christie NHS Trust Hospital, Manchester, UK, E Liakopoulou; Hospital Santa Creu I Sant Pau, Barcelona, Spain, J Sierra; University Tor Vergata, St Eugenio Hospital, Rome, Italy, W Arcese; University medical Centre St Radboud, Nijmejen, A Scattenberg; Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands, JJ Cornelissen; Hopital de Purpan, Toulouse, France, M Attal; Azienda Ospedali Riuniti di Ancona, Ancona (Torrette), Italy, A Olivieri; Cliniques Universitaires St. Luc, Brussels, Belgium, A Ferrant; Hospital Reina Sofia, Córdoba, Spain, A Torres-Gomez; Kantonsspital Aarau, Aarau, Switzerland, M Bargetzi; Hospedale Nord Taranto Italy, P Mazza; ULB - Hopital Erasme, Brussels, Belgium, W Feremans; Klinikum Nürnberg, Nürnberg, Germany, H Wandt; S Bortolo Hospital Vicenza, Italy, F Rodeghiero; University Hospital Gasthuisberg, Leuven, Belgium, J Maertens; University Hospital Bern, Bern, Switzerland, K Leibundgut; University Hospital Center Rebro, Zagreb, Croatia, B Labar; AZ Stuivenberg, Antwerp, Belgium, P Zachée; Medisch Spectrum Twente, Enschede, The Netherlands, MR Schaafsma; Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, JM Ribera Santasusana; Royal Perth Hospital, Perth, Australia, RP Herrmann; Hopital Saint Antoine, Paris, France, NC Gorin; Ospedale di Niguarda Ca Granda, Milano, Italy, E Morra; Hospital San Maurizio, Bolzano, Italy, P Coser; University Hospital, Olomouc, Czech Republic, K Indrák; Charité - Campus Benjamin Franklin, Berlin, Germany, L Uharek; Ege University Medical School, Bornova-Izmir, Turkey, S Cagirgan; Charles University Hospital, Pilsen, Czech Republic, V Koza.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herr, AL., Labopin, M., Blaise, D. et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 21, 129–135 (2007). https://doi.org/10.1038/sj.leu.2404461

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404461

Keywords

This article is cited by

Search

Advanced search

Quick links